Author/Authors :
Nemati, Saeed Cancer Research Center - Cancer Institute - Tehran University Medical of Sciences, Tehran, Iran , Hadji, Maryam Faculty of Social Sciences - Tampere University, Tampere, Finland , Seifi, Parissa Cancer Research Center - Cancer Institute - Tehran University Medical of Sciences, Tehran, Iran , Shirkhoda, Mohammad Department of Surgery - Cancer Institute - Tehran University of Medical Sciences, Tehran, Iran , Vand Rajabpour, Mojtaba Cancer Research Center - Cancer Institute - Tehran University Medical of Sciences, Tehran, Iran , Rajaei, Nazanin Cancer Research Center - Cancer Institute - Tehran University Medical of Sciences, Tehran, Iran , Aghili, Mahdi Radiation Oncology Department - Cancer Institute - Tehran University of Medical Sciences, Tehran, Iran , Mohagheghi, Mohammad Ali Cancer Research Center - Cancer Institute - Tehran University Medical of Sciences, Tehran, Iran , Zendehdel, Kazem Cancer Biology Research Center - Cancer Institute - Tehran University Medical of Sciences, Tehran, Iran
Abstract :
Background: Iran is a high-risk area with a poor prognosis for esophageal cancer.
We conducted the present study to evaluate the survival rate of esophageal cancer
after the introduction of neo-adjuvant chemo-radiation at the Cancer Institute of Iran.
Method: We performed a retrospective cohort study and abstracted the data of
421 patients who referred to the Cancer Institute of Iran between 2007 and 2011. Life
table and Kaplan-Meier approaches were applied to estimate 1-, 3-, and 5-year survival
rates and corresponding 95% confidence intervals (CI). Multiple Cox regression
model was recruited for investigating the association between 5-year survival rate
and prognostic factors.
Results:We found that 1-, 3-, and 5-year survival rates were 66.7%, 28.2, and 20.9%,
respectively. The hazard ratio (HR) was significantly higher among the patients who has
received definitive chemo-radiation therapy (Hazard ratio (HR) = 2.2, 95% confidence
interval (CI): 1.1, 4.2), surgery (HR= 2.0 95% CI: 1.0, 3.7), and palliative care (HR= 4.2,
95% CI: 2.1, 1.8) compared with those who received neo-adjuvant chemo-radiation and
surgery. We also found that the 5-year survival rate was doubled in the current study
conducted between 2007 and 2011 (20.9%) compared with the previous one conducted
between 1997 and 2006 (10.0%). Additionally, a considerable improvement was observed
in 1- and 3-year survival rate of esophageal cancer at the Cancer Institute of Iran.
Conclusion: Following the administration of neo-adjuvant chemo-radiation therapy,
the prognosis of esophageal cancer has improved significantly at the Cancer Institute
of Iran during the last decade. More data from other cancer centers and provinces of
Iran are required.
Keywords :
Esophagus , Neoplasms , Staging , Chemoradiation , Survival